nre clinical trials, inc.

220 cabrini blvd., #2a
new york, new york 10033

NYS Entity Status
ACTIVE

NYS Filing Date
JANUARY 02, 2014

NYS DOS ID#
4507743

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2014 - NRE CLINICAL TRIALS, INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • FDA Halts Merck’s Multiple Myeloma Trials After Patient Deaths
    By Frank Vinluan - Wednesday Jul 5, 2017

    Nearly a month after Merck paused enrollment in three clinical trials in multiple myeloma to gather more information about patient deaths, the FDA has now put a stop to those studies altogether. Merck (NYSE: MRK) said Wednesday that the FDA has placed a complete hold on two Phase 3 trials testing its immunotherapy drug pembrolizumab […]

    Source: Xconomy New York
  • Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study
    By Ben Fidler - Wednesday Nov 15, 2017

    Acorda Therapeutics’ rebuilding plan just suffered another setback, leaving the fate of one of the experimental Parkinson’s disease drugs that is closest to market unclear. Ardsley, NY-based Acorda (NASDAQ: ACOR) said Wednesday morning that it has seen troubling safety problems in a Phase 3 trial of its experimental Parkinson’s disease drug tozadenant. Acorda reported cases […]

    Source: Xconomy New York
  • Athenex IPO Raises $66M to Fund Clinical Trials for Cancer Drugs
    By Frank Vinluan - Wednesday Jun 14, 2017

    The IPO window is still open for clinical-stage drug companies, and Athenex is now the latest one to pass through it. The cancer drug developer raised $66 million through a public stock offering on Wednesday, funding that the company will devote mostly to a pair of cancer drugs in late-stage clinical development. Athenex priced its […]

    Source: Xconomy New York
  • Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing
    By Ben Fidler - Monday Sep 11, 2017

    A new drug for patients who have a hard time controlling their asthma could be nearing an FDA review. Tarrytown, NY-based Regeneron Pharmaceuticals (NASDAQ: REGN) and partner Sanofi this morning are touting results this morning from a 1,902-patient Phase 3 study called Liberty Asthma Quest. In it, their injectable antibody drug dupilumab (Dupixent), already approved […]

    Source: Xconomy New York
  • Clinical Drug Trials May Be Coming to Your Doctor's Office
    Tuesday Sep 12, 2017

    Electronic medical records make possible a new research model based on real-world evidence.

    Source: The Wall Street Journal: Opinion